Zacks Research Has Negative View of Teleflex FY2025 Earnings

Teleflex Incorporated (NYSE:TFX) – Research analysts at Zacks Research dropped their FY2025 earnings per share (EPS) estimates for Teleflex in a research report issued on Friday, November 14th. Zacks Research analyst Team now forecasts that the medical technology company will earn $14.02 per share for the year, down from their previous forecast of $14.04. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Teleflex’s current full-year earnings is $13.98 per share. Zacks Research also issued estimates for Teleflex’s Q4 2025 earnings at $3.71 EPS, Q1 2026 earnings at $3.05 EPS, Q2 2026 earnings at $3.73 EPS, Q3 2026 earnings at $3.90 EPS, FY2026 earnings at $14.92 EPS, Q1 2027 earnings at $3.74 EPS, Q2 2027 earnings at $4.09 EPS, Q3 2027 earnings at $4.31 EPS and FY2027 earnings at $16.40 EPS.

Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, November 6th. The medical technology company reported $3.67 EPS for the quarter, beating the consensus estimate of $3.38 by $0.29. The firm had revenue of $892.90 million during the quarter, compared to the consensus estimate of $892.79 million. Teleflex had a net margin of 6.31% and a return on equity of 15.08%. The business’s quarterly revenue was up 19.4% compared to the same quarter last year. During the same period last year, the firm earned $3.49 EPS. Teleflex has set its FY 2025 guidance at 14.000-14.200 EPS.

TFX has been the subject of a number of other reports. Wells Fargo & Company lowered their price target on shares of Teleflex from $131.00 to $114.00 and set an “equal weight” rating for the company in a report on Friday, November 7th. Mizuho increased their target price on Teleflex from $130.00 to $135.00 and gave the stock a “neutral” rating in a research note on Friday, August 1st. Wall Street Zen downgraded shares of Teleflex from a “buy” rating to a “hold” rating in a report on Saturday. Truist Financial reduced their price target on shares of Teleflex from $128.00 to $120.00 and set a “hold” rating for the company in a research report on Monday, November 10th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Teleflex in a research report on Thursday. One analyst has rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus price target of $134.57.

Teleflex Stock Down 2.3%

Shares of NYSE TFX opened at $106.94 on Monday. The firm’s 50 day simple moving average is $123.84 and its two-hundred day simple moving average is $122.07. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.41 and a quick ratio of 1.44. Teleflex has a one year low of $102.58 and a one year high of $195.47. The stock has a market capitalization of $4.73 billion, a P/E ratio of 25.16, a PEG ratio of 1.79 and a beta of 1.05.

Institutional Trading of Teleflex

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. MassMutual Private Wealth & Trust FSB grew its holdings in Teleflex by 57.9% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 210 shares of the medical technology company’s stock valued at $26,000 after purchasing an additional 77 shares during the period. Thompson Investment Management Inc. lifted its position in shares of Teleflex by 2.1% during the 2nd quarter. Thompson Investment Management Inc. now owns 4,970 shares of the medical technology company’s stock valued at $588,000 after buying an additional 100 shares in the last quarter. CX Institutional grew its stake in shares of Teleflex by 14.7% during the 2nd quarter. CX Institutional now owns 872 shares of the medical technology company’s stock valued at $103,000 after acquiring an additional 112 shares during the period. Signaturefd LLC increased its holdings in Teleflex by 38.3% in the 1st quarter. Signaturefd LLC now owns 433 shares of the medical technology company’s stock worth $60,000 after acquiring an additional 120 shares in the last quarter. Finally, Empirical Finance LLC raised its stake in Teleflex by 7.9% during the 1st quarter. Empirical Finance LLC now owns 1,690 shares of the medical technology company’s stock worth $234,000 after acquiring an additional 124 shares during the period. Institutional investors and hedge funds own 95.62% of the company’s stock.

Teleflex Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 15th. Shareholders of record on Friday, November 14th will be issued a dividend of $0.34 per share. The ex-dividend date is Friday, November 14th. This represents a $1.36 dividend on an annualized basis and a yield of 1.3%. Teleflex’s dividend payout ratio is -18.50%.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.